New Products

MUMBAI, India — The Food and Drug Administration has approved a generic diabetes drug made by Sun Pharmaceutical Industries, Sun said Friday.

The Indian generic drug maker announced the approval of repaglinide tablets in the 1-mg and 2-mg strengths, which are used in combination with diet and exercise to improve blood-sugar control in patients with Type 2 diabetes.

ALEXANDRIA, Va. — The National Community Pharmacists Association on Thursday announced the introduction of a resource kit — Take Charge of Rx Benefits in Your Community — to help preempt anti-patient drug benefit designs, such as those that require the use of mail-order facilities for prescription drugs.

LAS VEGAS — LashDip, a semi-permanent lash enhancement line that uses gel-based coating to make lashes lusher, has launched its first retail line.

It is not a lash extension or a strip; rather it is a weightless, gel-based coating that delivers all the perks of mascara but lasts for weeks.

NEW YORK — Looking to further innovate the at-home gel manicure market, Red Carpet Manicure has developed the first at-home light-activated nail treatments.

The manufacturer behind the diet-aid supplement Hydroxycut, Iovate Health Sciences International, recently introduced two new formats to its popular weight-loss franchise: Pro Clinical Hydroxycut Sprinkles and Pro Clinical Hydroxycut Gummies. The first represents a diet aid that is sprinkled on a diet-friendly food, such as a salad, that helps boost weight loss, and the second capitalizes on another booming trend in the supplement space — adult vitamins in gummy form.

PARSIPPANY, N.J. — Actavis is looking to become the first to market a generic drug for epilepsy, the company said Friday.

Actavis announced that it had filed with the Food and Drug Administration for lacosamide tablets in the 50-mg, 100-mg, 150-mg and 200-mg strengths. The drug is a generic version of UBC's Vimpat and is used to treat partial-onset seizures in epilepsy patients aged 17 and older.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new lung cancer drug made by Boehringer Ingelheim, the agency said Friday.

The FDA announced the approval of Gilotrif (afatinib) for patients with non-small cell lung cancer that has spread to other parts of the body and whose tumors include certain epidermal growth factor receptor gene mutations. The drug works by blocking proteins that promote the development of cancer cells.

NASHVILLE, Tenn. — A developer of revenue and payment cycle management and clinical information exchange software is expanding its payment network.

Emdeon announced Friday that it would expand the capabilities of the Emdeon Payment Network, a large, automated payment distribution system for the healthcare industry. The expansion includes the recent opening of a new 100,000-sq.-ft. facility in St. Louis dedicated to supporting the network, which currently reaches about 60,000 pharmacies, 500,000 providers, 81,000 dentists, 1,200 hospitals and 300 labs.